A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, and nadir CD4 T cell counts greater than 350 cells/mm3. Each participant will receive active vaccine/placebo at weeks 0, 4, 12, and 24 delivered by electroporation after intramuscular injection. The primary efficacy outcome will be based on HIV-specific immunologic assays at baseline and week 26.

You may be eligible for this study if you meet the following criteria:

• Conditions: ['HIV Infections']
• Age: 99 years or below
• Gender: All